Versartis ’ Phase III trial of somavaratan fails to meet endpoint for GHD
US-based biopharmaceutical firm Versartis has reported results from a Phase III clinical trial (VELOCITY) of somavaratan (VRS-317) to treat paediatric patients with growth hormone deficiency (GHD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news
AbbVie and BMS to investigate combination therapy in solid tumour trials
AbbVie and Bristol-Myers Squibb (BMS) have entered a clinical trial collaboration to assess ABBV-399 in combination with Opdivo (nivolumab) to treat patients with non-small-cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news
Cavion starts enrolment in Phase II trial of CX-8998 for essential tremor
US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat essential tremor (ET). (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news
Shire reports positive data from Phase III trial of Intuniv for ADHD
Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder ( … (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news
Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma
Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news
Audentes commences dosing in Phase I/II trial for myotubular myopathy
US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM). (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics
Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock. (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2017 Category: Pharmaceuticals Source Type: news
AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD
US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to Alzheimer ’s disease (MCI due to AD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news
Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer
The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat … (Source: Drug Development Technology)
Source: Drug Development Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news
Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers
Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news
Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis
Janssen Research& Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news
Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news
Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial
Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news
Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial
Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAF É ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2017 Category: Pharmaceuticals Source Type: news
Australian cancer centres launch personalised medicine trial for childhood cancers
Cancer centres in Australia have launched a national clinical trial under the Zero Childhood Cancer programme to evaluate personalised medicine for childhood cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2017 Category: Pharmaceuticals Source Type: news
